CIPDB › China Industry › Chemicals › Pharmaceutical Intermediate
Shanghai Pemichem Lab Supply Raw Materials Pharmaceutical Intermediates Powder Retatrutide CAS 2381089-83-2 API with 99% Pruity1
Pharmaceutical IntermediateCAS 2381089-83-22381089-83-2
Shanghai Pemichem Biotechnology Co., Ltd.
Preview:
Product Description 1.For some materials, we could supply free Samples for testing at first..2.MOQ: 1g or 5g3.More than 3000 kinds of materials in stock.4.More than 11+ manufacturing experience.5.Certification: MSDS,HALAL,COA,IFRA,ISO9001, ISO22000,26 Allergens, etc.6.Lead time:about 8-12 working days.8.Verified by Made-in-China as Golden Supplier.9.We will reply you for your inquiry in 24 hours.10. Our Q&C team will inspect every product quality strictly before delivery.What is CAS 2381089-83-2 Retatrutide Powder? Product Name:RetatrutideCAS:2381089-83-2MF: MW:0EINECS:200-001-8Product Categories: Mol File:Mol File Retatrutide Chemical Propertiesstorage temp. -20°Cform powdercolor White lyophilizedWater Solubility Soluble in water (5mg/ml). Safety Information MSDS Information Retatrutide Usage And SynthesisDescriptionRetatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent in sulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent in sulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating ins ulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.Biological ActivityRetatrutide (LY3437943), a single peptide conjugated to a lipid diacid molecule, exerts a powerful agonist effect on the human glucagon‐receptor (GCGR), GIPR, and GLP‐1R. In comparison with the human glucagon and glucagon‐like peptide 1 (GLP‐1), retatrutide exhibits reduced potency (by a factor of 0.3 and 0.4, respectively) on the GCGR and GLP‐1R while displaying enhanced potency at the human GIPR (by a factor of 8.9) when compared to the glucose‐dependent ins ulinotropic polypeptide (GIP)[7].Mechanism of actionWhen injected into mice suffering from diabetes-induced kidney injury, retatrutide was found to markedly reduce albuminuria levels while also increasing renal filtration rate. This was attributed to its ability to activate GLP-1R/GR-dependent signalling pathways, which then produced anti-inflammatory and antiapoptotic effects that protected the kidneys from further damage. Additionally, it has been shown to directly modulate glomerular permeability, thus leading to improved urinary concentration. Initial results indicate that the peptide can induce marked improvements in albuminuria levels within just four weeks of treatment when compared to other treatments for chronic kidney disease such as ACE inhibitors or angiotensin receptor blockers (ARBs). Moreover, retatrutide has demonstrated a greater effect than either ACE inhibitors or ARBs at reducing systolic blood pressure without inducing significant side effects.Side effectsThe most common side effects of retatrutide are gastrointestinal, including: Nausea, Diarrhea, Vomiting, and Constipation. At higher doses, researchers stated these symptoms were "mostly mild to moderate in severity" and typically treated by lowering the dosage. However, 7% of patients also experienced skin tingling. At 24 weeks of treatment, patients' heart rates on higher doses peaked but declined afterward.in vitroIn vitro, Retatrutide demonstrates similar efficacy to natural glucagon in evoking glucose production within hepatocytes. Meanwhile, in adipocytes, it surpasses native GIP in inducing lipolysis. Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity. Retatrutide demonstrates dosage‐dependent pharmacokinetics, featuring a favourable half‐life of nearly 6 days, enabling convenient weekly administration. Additionally, GLP‐1 and GCG are known to significantly delay GE in humans, while GIP may have no impact on GE. Delayed GE reduces food consumption and, therefore, leads to weight reduction[7].References1. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: T. Coskun, et al.; Cell Metab. 34, 1234 (2022) DOI:10.1016/j.cmet.2022.07.0132. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying: S. Urva, et al.; Diabetes Obes. Metab. 25, 2784 (2023) DOI:10.1111/dom.151673. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial: S. Urva, et al.; Lancet 400, 1869 (2022) DOI:10.1016/S0140-6736(22)02033-54. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? S.A. Doggrell; Expert Opin. Investig. Drugs 32, 355 (2023) DOI:10.1080/13543784.2023.22065605. Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943: A. Regmi & W. Roell; STAR Protoc. 4, 102304 (2023) DOI:10.1016/j.xpro.2023.1023046. Gut hormone co-agonists for the treatment of obesity: from bench to bedside: R. Nogueiras, et al.; Nature Metab. 5, 933 (2023) (Review) DOI:10.1038/s42255-023-00812-z7. Muhammad Naeem, Umm E Salma Shabbar Banatwala, Laiba Imran. "Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence." Health Science Reports 7 2 (2024). Retatrutide Preparation Products And Raw materials Tag:Retatrutide(2381089-83-2) Related Product Information Clarify:Our peptides is just for Reseach&Lab use,not used on Human body. ShangHai Pemichem is one of professional company specialized in research, development, custom manufacturing and trading of pharmaceutical API, advanced intermediates, Cosmetic raw materials, health and new raw materials, polypeptides, animal drug and organic reagent etc. You can select more than 2000 kinds of raw ingredients here. And we are keeping developing new products and continuously marketing them for sale. You will save lots of time , energy, money and have a very pleasant cooperation with us!Our purpose: Trransaction is not the end, but the satarting of service! Q&A1.How could l get a sample?Before we received the first order, please afford the sample cost and express fee. We will return the sample cost back to you within your first order.2.Can you make designs for us?We have a professional design team to help our customers do design work.Both OEM and ODM orders are accepted.3.Whether you could make our brand on your products?Yes. We can print your Logo on both the products and the packages if you can meet our MOQ.4.How can you provide us high quality products?We have a professional QC team, every product is shipped after strictly examination.5.What is your lead time?7-15days, We will update you eact two-three days!6.What is your payment?We accept T/T.L/C.Paypal.Westem union or to be negotiated.Don't worry about anything, if you have any problems, please feel free to contact us
Purchasing Agent
Note: Send your message to supplier or manufacturer.
Welcome to our Professional and comprehensive procurement services...